Events
AltaThera attending CHOP Cardiology 2026 in Scottsdale
AltaThera attended the CHOP Cardiology 2026 meeting in Scottsdale, AZ
AltaThera attended the CHOP Cardiology 2026 meeting in Scottsdale, AZ
In July 2025, the U.S. Food and Drug Administration approved a label expansion for Sotalol IV, adding a new indication for pediatric patients with life-threatening ventricular arrhythmias and for the maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter. This approval reflects AltaThera’s ongoing commitment to expanding access to personalized antiarrhythmic therapy for patients of all ages.
AltaThera Pharmaceuticals showcased Sotalol IV at Heart Rhythm Society’s annual meeting in Boston from May 16-19, 2024. Serving as a hub for innovation, discovery, and connection, HRS brings the world of electrophysiology together with over 8,500 attendees from around the world.